This bill cracks down on a sneaky tactic some drug companies use to block their competitors. Here's what happens: when a generic drug maker applies to the FDA to sell a cheaper version of an existing drug, sometimes the brand-name drug company will file a complaint with the FDA that they know is completely baseless—just to slow things down and keep the generic drug off the market longer. This bill makes that practice illegal and gives the Federal Trade Commission (FTC) the power to sue companies that do it. If a company gets caught filing one of these bogus complaints, they could face serious fines—up to $50,000 for each day the FDA spent reviewing their fake petition. Essentially, this protects generic drug makers from being harassed with frivolous legal challenges and helps get cheaper medications to patients faster. It's designed to keep the drug market competitive and prevent big pharmaceutical companies from using the regulatory system as a weapon against smaller competitors.

Stop STALLING Act

Klobuchar, Amy

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA.	 A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.